تحميل...
Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy
Antibody-drug conjugates (ADCs) have exhibited potent clinical benefits in cancer therapy. However, development of ADCs against epidermal growth factor receptor (EGFR) has limitations because of wide expression of EGFR in both normal and tumor tissues. Previously, we developed an anti-EGFR protease-...
محفوظ في:
| الحاوية / القاعدة: | MAbs |
|---|---|
| المؤلفون الرئيسيون: | , , , , , , , , , , |
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Taylor & Francis
2016
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4966596/ https://ncbi.nlm.nih.gov/pubmed/26760045 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2015.1127491 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|